Home The Word Brain | My Amedeo FAQ Privacy About | ||||||||||
The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al. |
Ovarian Neoplasms |
Free Subscription
1 Ann Oncol |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Ovarian Neoplasms is free of charge.
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology
and molecular biology and early, advanced and recurrent disease.
Ann Oncol. 2024 Jan 29:S0923-7534(23)05103-7. doi: 10.1016/j.annonc.2023.
PubMed
Abstract available
Primary results and characterization of patients with exceptional outcomes in a
phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for
BRCA wild-type, platinum-sensitive, recurrent ovarian cancer.
Cancer. 2024 Jan 30. doi: 10.1002/cncr.35222.
PubMed
Abstract available
Associations of serum trimethylamine N-oxide and its precursors with colorectal
cancer risk in the Prostate, Lung, Colorectal, Ovarian Cancer Screening Trial
Cohort.
Cancer. 2024 Jan 29. doi: 10.1002/cncr.35219.
PubMed
Abstract available
Evaluation of Homologous Recombination Deficiency in Ovarian Cancer.
Curr Treat Options Oncol. 2024 Feb 1. doi: 10.1007/s11864-024-01176.
PubMed
Abstract available
Antibody-Drug Conjugates in Gynecologic Cancers.
Curr Treat Options Oncol. 2024;25:1-19.
PubMed
Abstract available
Characterization of hypoxia-responsive states in ovarian cancer to identify hot
tumors and aid adjuvant therapy.
Discov Oncol. 2024;15:23.
PubMed
Abstract available
CD137+ tumor infiltrating lymphocytes predicts ovarian cancer survival.
Gynecol Oncol. 2024;184:74-82.
PubMed
Abstract available
Concordance between an FDA-approved companion diagnostic and an alternative assay
kit for assessing homologous recombination deficiency in ovarian cancer.
Gynecol Oncol. 2024;184:67-73.
PubMed
Abstract available
Real-world outcomes associated with bevacizumab combined with chemotherapy in
platinum-resistant ovarian Cancer.
Gynecol Oncol. 2024;184:51-56.
PubMed
Abstract available
Real world data of niraparib in platinum sensitive relapsed ovarian cancer: A
multicenter experience of the MITO group.
Gynecol Oncol. 2024;184:24-30.
PubMed
Abstract available
Rates of genetic consultation in high-grade serous ovarian cancer patients in the
era of PARP inhibitor therapy: A population-based study.
Int J Gynaecol Obstet. 2024 Jan 29. doi: 10.1002/ijgo.15391.
PubMed
Abstract available
Advances in the role of GPX3 in ovarian cancer (Review).
Int J Oncol. 2024;64:31.
PubMed
Abstract available
Compelling Story of Ovarian Cancer Screening.
J Clin Oncol. 2024 Feb 2:JCO2302424. doi: 10.1200/JCO.23.02424.
PubMed
PARP1-stabilised FOXQ1 promotes ovarian cancer progression by activating the
LAMB3/WNT/beta-catenin signalling pathway.
Oncogene. 2024 Jan 31. doi: 10.1038/s41388-024-02943.
PubMed
Abstract available
Enhancing the therapeutic efficacy of NK cells in the treatment of ovarian cancer
(Review).
Oncol Rep. 2024;51:50.
PubMed
Abstract available
Life Experience of Survivors of Gynecologic Cancers: A Survey Conducted in Italy.
Oncology (Williston Park). 2024;38:15-19.
PubMed
Abstract available
Expression of Concern: Minocycline Suppresses Interleukine-6, Its Receptor System
and Signaling Pathways and Impairs Migration, Invasion and Adhesion Capacity of
Ovarian Cancer Cells: In Vitro and In Vivo Studies.
PLoS One. 2024;19:e0298444.
PubMed
Cost-effectiveness analysis of olaparib maintenance therapy for BRCA mutation
ovarian cancer in the public sector in Malaysia.
PLoS One. 2024;19:e0298130.
PubMed
Abstract available
Thank you for your interest in scientific medicine.